27,380 Alzheimer's and dementia studies in plain English, each scored out of 100.
The incidence rate of dementia in Europe and North America has declined by 13% per decade over the past 25 years, consistently across studies. 2 key findings →
Design: cohort study Participants: 49,202 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
Resveratrol was safe and well-tolerated. 4 key findings →
Design: clinical trial Participants: 119 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Antihypertensive use was associated with decreased AD but not non-AD risk throughout late life. 5 key findings →
Design: meta-analysis Participants: 31,250 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
These findings reveal the potential for anti-Aβ therapies to compromise long-term brain health by accelerating brain atrophy and provide new insight into the adverse impact of ARIA. 4 key findings →
Design: systematic review Participants: 8,062 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
There was no evidence that aspirin was effective in reducing risk of dementia, MCI, or cognitive decline. 2 key findings →
Participants: 19,114 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Older adults with higher triglyceride levels within the normal to high-normal range had a lower dementia risk and slower cognitive decline over time compared with individuals with lower triglyceride levels. 5 key findings →
Design: randomized controlled trial Participants: 13,976 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
A healthy lifestyle as a composite score is associated with a substantially lower risk of Alzheimer's dementia. 5 key findings →
Design: meta-analysis Participants: 1,845 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
The number of people in the United States with AD dementia will increase dramatically in the next 40 years unless preventive measures are developed. 1 key finding →
Design: longitudinal study Participants: 1,913 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
PDE5I initiation in men with ED was associated with a lower risk of AD, particularly in those most frequently issued prescriptions. 5 key findings →
Design: randomized controlled trial Participants: 269,725 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Significant proportions of the observed variance in age at symptom onset in ADAD can be explained by family history and mutation type, providing empirical support for use of these data to estimate onset in clinical research. 2 key findings →
Participants: 3,275 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Simvastatin had no benefit on the progression of symptoms in individuals with mild to moderate AD despite significant lowering of cholesterol. 4 key findings →
Participants: 406 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
In this study, we found that ePVS counts were not associated with cognitive dysfunction in the general population. 5 key findings →
Design: meta-analysis Participants: 3,575 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
No significant differences were found in the primary efficacy analysis. 2 key findings →
Design: clinical trial Participants: 234 Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
We identified 2 core dimensions of heterogeneity: typicality and severity. 2 key findings →
Design: systematic review Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Although prespecified criteria for testing treatment effects were not met, these data suggest a potential treatment effect in patients with mild AD treated with high-dose crenezumab. 4 key findings →
Design: clinical trial Participants: 184 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
In cognitively intact individuals at risk, sustained treatment with naproxen sodium 220 mg twice daily increases frequency of adverse health effects but does not reduce apparent progression of presymptomatic AD. 4 key findings →
Participants: 195 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Based on the results of the prespecified coprimary endpoints, this study was negative. 5 key findings →
Design: clinical trial Participants: 624 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
MCI prevalence was 6.7% for ages 60-64, 8.4% for 65-69, 10.1% for 70-74, 14.8% for 75-79, and 25.2% for 80-84. 1 key finding →
Evidence: low
Full summary, score breakdown and related studies → Original source Free full text
Plasma tau partly reflects AD pathology, but the overlap between normal aging and AD is large, especially in patients without dementia. 3 key findings →
Design: longitudinal study Participants: 179 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
MCR is common in older adults, and is a strong and early risk factor for cognitive decline. 3 key findings →
Design: cohort study Participants: 26,802 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
We tested the hypothesis that plasma neurofilament light chain (NfL) identifies asymptomatic carriers of familial frontotemporal lobar degeneration (FTLD)-causing mutations at risk of disease progression. 4 key findings →
Design: longitudinal study Participants: 277 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
We included randomized controlled trials (RCTs) and nonrandomized controlled studies at lower risk of bias comparing ChEI treatment with placebo or usual treatment, for 6 months or longer, in patients with dementia of any type. 5 key findings →
Design: systematic review Participants: 79,153 Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Neuroinflammation and cerebrovascular dysfunction are early events occurring already at presymptomatic stages of AD and contribute to disease progression. 5 key findings →
Design: longitudinal study Participants: 508 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
The best CSF measures for identifying MCI-AD were Aβ42/total tau (t-tau) and Aβ42/hyperphosphorylated tau (p-tau) (area under the curve [AUC] 0.93-0.94). 3 key findings →
Design: longitudinal study Participants: 122 Evidence: moderate
Full summary, score breakdown and related studies → Original source Free full text
In response to sleep loss (+17.2%), compared with normal sleep (+1.8%), the evening to morning ratio was increased for t-tau ( p = 0.035). 4 key findings →
Evidence: high
Full summary, score breakdown and related studies → Original source Free full text
Free full text links and the Full text may need a subscription label come from Unpaywall, Europe PMC and OpenAlex records of free copies, checked 10 Oct 2026. A study with neither is unknown, not paywalled.
This is alzhub's own score. It is not an official metric, not an impact factor, and no journal, publisher or ranking body endorses it. We built it so that a reader who is not a scientist can tell a landmark trial from a conference abstract without having to already know the difference. Every point comes from one of 20 components, all of them printed on the study itself, so you can disagree with our arithmetic rather than having to trust the total.
Journals are placed in ordered tiers, never given a numeric impact factor — we could not verify current impact factors from a source we control, and an invented one would be worse than none. Tier 1 is the top-tier general journals (NEJM, The Lancet, JAMA, Nature, Science, Nature Medicine); tier 2 is the leading specialty journals; tier 3 is every other peer-reviewed journal. A separate part scores how much the journal's own papers are cited, which tells the tier-3 journals apart.
Two rules we don't bend. First, we never fill in a missing value: if a record does not state a sample size or a design, that component scores zero, and if we simply have no data for a part, such as a citation count, that part is left out and the study is scored on the parts we could check. The study card says which. Second, anything that is not a peer-reviewed article is capped at 16/100 and carries a warning chip — so a conference abstract or a company press release can never outrank a peer-reviewed paper, no matter how good it looks.
We rank a rigorous null result — a good trial showing that something does not work — above an early positive finding. Someone deciding whether to buy a supplement is served by that, and the rigour is already counted by the design and journal components.
The score is computed from the published data alone and is reproducible: the same file always yields the same numbers.
See the whole rubric drawn out → — four charts covering all 27,380 studies: how the scores are spread and where the cap bites, which of the 20 components the library is strong and weak on, which subjects rest on stronger evidence, and what kinds of study each subject is actually built from.
This is a large sample of the Alzheimer's literature, not an exhaustive index of it. It holds 27,380 records, built mostly from automated pulls of Europe PMC (60.6% of the library) and OpenAlex (18.6%), plus smaller pulls from PubMed, Crossref and medRxiv. If a study, a drug, or a finding isn't here, that is not evidence it doesn't exist in the literature — it may simply not have been pulled in yet.
1,032 records (3.8% of the library) are not peer-reviewed — 962 of those are preprints posted before any journal review, and the rest are conference abstracts, regulatory notices and reports. Every study card on this page states its status plainly, and the score above is capped for anything that isn't a peer-reviewed article.
See the full, machine-readable breakdown of this library's coverage →